Lilly's triple agonist has won four phase 3 trials and is due for US filing in early 2027. Until then, anything sold online as retatrutide is unapproved and of unknown quality.
Six patients treated with Beam's BEAM-301 needed less cornstarch and fasted longer, but follow-up is short and the lower-dose effect waned.
The first WRN helicase inhibitor tested in humans held disease stable in three quarters of patients with microsatellite instability tumours, but shrank only one in ten.
PLA2G2F climbs in ageing neurons, protects memory in mice when boosted, and is most active in people whose cognition survived amyloid pathology.
A platform called OSAR assembled 31 of 34 large bacterial gene clusters and produced 29 peptides, turning a months-long bespoke process into a batch workflow.
The agency's Transparency Roadmap makes rejection letters standing practice and proposes disclosing that applications exist, but most of it remains intention rather than rule.
SELUTION4SFA randomized 300 patients with narrowed leg arteries and met both its efficacy and safety endpoints, offering the field an alternative to paclitaxel.
A randomized trial found AI-written summaries improved consultations and cut them by eight minutes. A companion study found AI-recommended care cost 3.2 times what physicians ordered.
Eplontersen missed its primary endpoint in 1,432 patients with amyloid cardiomyopathy, yet slowed functional decline. The explanation lies in what patients were already taking.
Two October papers pull together every trial of CAR T-cells made inside the body: 41 patients, responses in all four myeloma cases, and a median progression-free survival of four months.
Roche will pay Hangzhou-based Defand to screen for molecular glue degraders in cancer and immunology, a sign of growing interest in drugs that destroy proteins rather than block them.
A new white paper sets out a fit-for-purpose approach to reviewing rare disease drugs and biologics, from pre-IND meetings through manufacturing and post-approval obligations.